N/A N=79 Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
Upper Back Pain
Primary: Mean Change From Baseline of Both AM and PM Spasm Assessment Scores — 1.66; 1.87; 1.91; 1.54 Score on a Scale — p=0.68
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=405 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease — NA; NA; NA; NA Titer
N/A N=52 Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Liver Neoplasms · Adenoma · Carcinoma
Primary: Percentage of Participants With Overall Change in Additional Diagnostic Information Obtained When Comparing the Combined Precontrast/Postcontrast Images With the…
Phase 2 N=140 Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
Genotype 1 Chronic Hepatitis C
Primary: EVR (Early Virologic Response) — 79.4; 78.5 percentage of participants — p=1.000
Phase 3 N=1,250 A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
Non-small Cell Lung Cancer
Primary: Disease Free Survival (DFS) — 50.5; 48.2 months — p=0.3235
Phase 4 N=689 Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment — -0.99; -0.98 percent — p=<0.0001
Phase 4 N=190 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48 — 11.57; 6.43; 16.36 Units on a scale
N/A N=594 Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
Major Depressive Disorder
Primary: Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9) — 14.6; 6.1; 8.5 units on a scale — p=0.000
Phase 2 N=176 Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 5; 3; 10; 17 participants
Phase 2 N=32 PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Melanoma (Skin)
Primary: Plasma b-FGF Level Response — 34.5 percentage of participants — p=<0.001
Phase 4 N=83 Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
Atrial Fibrillation
Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048
N/A N=77 TOCCATA - Touch+™ for Catheter Ablation
Atrial Fibrillation · Tachycardia, Supraventricular
Primary: Number of Subjects With Operative and Post-operative Serious Adverse Events — 4; 1 participants
Phase 3 N=90 A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease
Advanced Parkinson's Disease
Primary: Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period — 61; 22; 3; 3 participants
N/A N=67 Study of the Effectiveness of Green Diode Laser Light on Body Shaping
Body Contouring
Primary: Combined Circumference in Inches of the Waist, Hips and Bilateral Thighs — -3.895; -1.136 inches
Phase 1 N=37 A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Non-Small Cell Lung Carcinoma · Breast Cancer · Melanoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants